
1. J Int AIDS Soc. 2014 Aug 11;17:19064. doi: 10.7448/IAS.17.1.19064. eCollection
2014.

Re-testing and misclassification of HIV-2 and HIV-1&2 dually reactive patients
among the HIV-2 cohort of the West African Database to evaluate AIDS
collaboration.

Tchounga BK(1), Inwoley A(2), Coffie PA(3), Minta D(4), Messou E(5), Bado G(6),
Minga A(7), Hawerlander D(8), Kane C(9), Eholie SP(3), Dabis F(10), Ekouevi
DK(11); WADA Collaboration.

Author information: 
(1)Centre INSERM U897-Epidémiologie-Biostatistique, ISPED, Université de
Bordeaux, Bordeaux, France; Inserm U897, ISPED, Université de Bordeaux, Bordeaux,
France; Programme PACCI, Site de recherche ANRS, Abidjan, Côte d'Ivoire;
boris.tchounga@yahoo.fr.
(2)Centre de Diagnostic et de Recherche sur le SIDA et les Affections
Opportunistes, CHU de Treichville, Abidjan, Côte d'Ivoire.
(3)Programme PACCI, Site de recherche ANRS, Abidjan, Côte d'Ivoire; Service des
Maladies Infectieuses et Tropicales, CHU de Treichville, Abidjan, Côte d'Ivoire.
(4)Centre de Prise en Charge des Personnes vivant avec le VIH, Hôpital du Point
G, Bamako, Mali.
(5)Programme PACCI, Site de recherche ANRS, Abidjan, Côte d'Ivoire; Centre de
Prise en Charge de Recherche et de Formation, CePReF-Aconda-VS, Abidjan, Côte
d'Ivoire.
(6)Hôpital de Jour, Service des Maladies Infectieuses et Tropicales, CHU Souro
Sanou, Bobo Dioulasso, Burkina Faso.
(7)Programme PACCI, Site de recherche ANRS, Abidjan, Côte d'Ivoire; Centre
Médical de Suivi de Donneurs de Sang/CNTS/PRIMO-CI, Abidjan, Côte d'Ivoire.
(8)Centre Intégré de Recherches Biocliniques d'Abidjan CIRBA, Abidjan, Côte
d'Ivoire.
(9)Laboratoire de Bactériologie-Virologie, Département GC&BA-ESP/UCAD, CHU A Le
Dantec, Dakar, Sénégal.
(10)Centre INSERM U897-Epidémiologie-Biostatistique, ISPED, Université de
Bordeaux, Bordeaux, France; Inserm U897, ISPED, Université de Bordeaux, Bordeaux,
France.
(11)Centre INSERM U897-Epidémiologie-Biostatistique, ISPED, Université de
Bordeaux, Bordeaux, France; Inserm U897, ISPED, Université de Bordeaux, Bordeaux,
France; Programme PACCI, Site de recherche ANRS, Abidjan, Côte d'Ivoire;
Département des Sciences Fondamentales et Santé Publique, Université de Lomé,
Lomé-Togo.

Comment in
    J Int AIDS Soc. 2015;18(1):19460.
    J Int AIDS Soc. 2015;18(1):19380.

INTRODUCTION: West Africa is characterized by the circulation of HIV-1 and HIV-2.
The laboratory diagnosis of these two infections as well as the choice of a
first-line antiretroviral therapy (ART) is challenging, considering the limited
access to second-line regimens. This study aimed at confirming the classification
of HIV-2 and HIV-1&2 dually reactive patients followed up in the HIV-2 cohort of 
the West African Database to evaluate AIDS collaboration.
METHOD: A cross-sectional survey was conducted from March to December 2012 in
Burkina Faso, Côte d'Ivoire and Mali among patients classified as HIV-2 or
HIV-1&2 dually reactive according to the national HIV testing algorithms. A 5-ml 
blood sample was collected from each patient and tested in a single reference
laboratory in Côte d'Ivoire (CeDReS, Abidjan) with two immuno-enzymatic tests:
ImmunoCombII® (HIV-1&2 ImmunoComb BiSpot - Alere) and an in-house ELISA test,
approved by the French National AIDS and hepatitis Research Agency (ANRS).
RESULTS: A total of 547 patients were included; 57% of them were initially
classified as HIV-2 and 43% as HIV-1&2 dually reactive. Half of the patients had 
CD4≥500 cells/mm(3) and 68.6% were on ART. Of the 312 patients initially
classified as HIV-2, 267 (85.7%) were confirmed as HIV-2 with ImmunoCombII® and
in-house ELISA while 16 (5.1%) and 9 (2.9%) were reclassified as HIV-1 and
HIV-1&2, respectively (Kappa=0.69; p<0.001). Among the 235 patients initially
classified as HIV-1&2 dually reactive, only 54 (23.0%) were confirmed as dually
reactive with ImmunoCombII® and in-house ELISA, while 103 (43.8%) and 33 (14.0%) 
were reclassified as HIV-1 and HIV-2 mono-infected, respectively (kappa= 0.70;
p<0.001). Overall, 300 samples (54.8%) were concordantly classified as HIV-2, 63 
(11.5%) as HIV-1&2 dually reactive and 119 (21.8%) as HIV-1 (kappa=0.79;
p<0.001). The two tests gave discordant results for 65 samples (11.9%).
CONCLUSIONS: Patients with HIV-2 mono-infection are correctly discriminated by
the national algorithms used in West African countries. HIV-1&2 dually reactive
patients should be systematically investigated, with a standardized algorithm
using more accurate tests, before initiating ART as at least 4 out of 10 of them 
could initiate an effective first-line ART for HIV-1 and optimize their
second-line treatment options.

DOI: 10.7448/IAS.17.1.19064 
PMCID: PMC4134669
PMID: 25128907  [Indexed for MEDLINE]

